FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067328810> ?p ?o ?g. }

• W2067328810 abstract "Introduction: Invasive transitional cell carcinoma of the urinary bladder (InvTCC) kills >14,000 people yearly in the US. Folate receptors (FRs, especially FRα) are being targeted for imaging and therapy across multiple cancer types. This work was performed to define FR expression and uptake in InvTCC, with comparison to normal bladder; and to determine the antitumor activity and toxicity of folate-targeted vinblastine in dogs with naturally-occurring InvTCC where the cancer closely mimics human InvTCC. Canine InvTCC metastasizes frequently, and only 35% of dogs have remission with chemotherapy. Methods: Immunohistochemistry (IHC, mab343, PU17, FRβmab) was performed in InvTCC, bladder tissues adjacent to InvTCC in humans, and in bladder from normal dogs. Folate uptake was determined ex vivo by folate binding assay, and in vivo in dogs with InvTCC by nuclear scintigraphy ( 99m Tc based FR targeted imaging agent). A dose escalation study of folate-targeted vinblastine (EC0905, IV weekly) was performed in dogs with biopsy-confirmed, FR-positive, measurable InvTCC. Toxicity (VCOG criteria) was assessed by CBCs, serum chemistry profiles, urinalyses, physical exams, and dog owner observations. The MTD was defined as the highest dose at which 0 of 6 dogs had grade 4 toxicity and ≤1 of 6 dogs had grade 3 toxicity. Tumor response was assessed by ultrasonography (with detailed bladder mapping) and radiography. Results: FR expression (IHC, PU17) was noted in the majority of canine samples including 56 of 74 (76%) primary tumors, 7 of 12 (58%) nodal metastases, and 10 of 21 (48%) lung metastases, as well as in normal urothelium. Typically, >50% of tumor cells were positive. FR expression was cytoplasmic in 18, membrane in 6, and in both sites in 32 InvTCC cases. Scintigraphy (n= 12 dogs) revealed folate uptake in primary and metastatic lesions. The MTD of EC0905 in dogs was 0.25 mg/kg IV weekly. At doses above the MTD, gastrointestinal upset and myelosuppression occurred. No urologic toxicity was noted. Tumor responses included partial remission (≥50% reduction in tumor volume) in 5 dogs and stable disease ( Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-5. doi:1538-7445.AM2012-LB-5" @default.
• W2067328810 created "2016-06-24" @default.
• W2067328810 creator A5015130724 @default.
• W2067328810 creator A5019247175 @default.
• W2067328810 creator A5019856313 @default.
• W2067328810 creator A5025810259 @default.
• W2067328810 creator A5031023089 @default.
• W2067328810 creator A5042026897 @default.
• W2067328810 creator A5048434031 @default.
• W2067328810 creator A5051203203 @default.
• W2067328810 creator A5058610683 @default.
• W2067328810 creator A5062115544 @default.
• W2067328810 creator A5081934792 @default.
• W2067328810 creator A5085542989 @default.
• W2067328810 creator A5089609044 @default.
• W2067328810 date "2012-04-15" @default.
• W2067328810 modified "2023-09-25" @default.
• W2067328810 title "Abstract LB-5: Folate-targeted therapy for invasive urinary bladder cancer" @default.
• W2067328810 doi "https://doi.org/10.1158/1538-7445.am2012-lb-5" @default.
• W2067328810 hasPublicationYear "2012" @default.
• W2067328810 type Work @default.
• W2067328810 sameAs 2067328810 @default.
• W2067328810 citedByCount "0" @default.
• W2067328810 crossrefType "proceedings-article" @default.
• W2067328810 hasAuthorship W2067328810A5015130724 @default.
• W2067328810 hasAuthorship W2067328810A5019247175 @default.
• W2067328810 hasAuthorship W2067328810A5019856313 @default.
• W2067328810 hasAuthorship W2067328810A5025810259 @default.
• W2067328810 hasAuthorship W2067328810A5031023089 @default.
• W2067328810 hasAuthorship W2067328810A5042026897 @default.
• W2067328810 hasAuthorship W2067328810A5048434031 @default.
• W2067328810 hasAuthorship W2067328810A5051203203 @default.
• W2067328810 hasAuthorship W2067328810A5058610683 @default.
• W2067328810 hasAuthorship W2067328810A5062115544 @default.
• W2067328810 hasAuthorship W2067328810A5081934792 @default.
• W2067328810 hasAuthorship W2067328810A5085542989 @default.
• W2067328810 hasAuthorship W2067328810A5089609044 @default.
• W2067328810 hasConcept C121608353 @default.
• W2067328810 hasConcept C126322002 @default.
• W2067328810 hasConcept C126894567 @default.
• W2067328810 hasConcept C142724271 @default.
• W2067328810 hasConcept C150903083 @default.
• W2067328810 hasConcept C204232928 @default.
• W2067328810 hasConcept C207001950 @default.
• W2067328810 hasConcept C26291073 @default.
• W2067328810 hasConcept C2775934546 @default.
• W2067328810 hasConcept C2776694085 @default.
• W2067328810 hasConcept C2777132456 @default.
• W2067328810 hasConcept C2779762690 @default.
• W2067328810 hasConcept C2780306303 @default.
• W2067328810 hasConcept C2780352672 @default.
• W2067328810 hasConcept C2781230642 @default.
• W2067328810 hasConcept C29730261 @default.
• W2067328810 hasConcept C71924100 @default.
• W2067328810 hasConcept C77411442 @default.
• W2067328810 hasConcept C86803240 @default.
• W2067328810 hasConcept C90924648 @default.
• W2067328810 hasConcept C96232424 @default.
• W2067328810 hasConceptScore W2067328810C121608353 @default.
• W2067328810 hasConceptScore W2067328810C126322002 @default.
• W2067328810 hasConceptScore W2067328810C126894567 @default.
• W2067328810 hasConceptScore W2067328810C142724271 @default.
• W2067328810 hasConceptScore W2067328810C150903083 @default.
• W2067328810 hasConceptScore W2067328810C204232928 @default.
• W2067328810 hasConceptScore W2067328810C207001950 @default.
• W2067328810 hasConceptScore W2067328810C26291073 @default.
• W2067328810 hasConceptScore W2067328810C2775934546 @default.
• W2067328810 hasConceptScore W2067328810C2776694085 @default.
• W2067328810 hasConceptScore W2067328810C2777132456 @default.
• W2067328810 hasConceptScore W2067328810C2779762690 @default.
• W2067328810 hasConceptScore W2067328810C2780306303 @default.
• W2067328810 hasConceptScore W2067328810C2780352672 @default.
• W2067328810 hasConceptScore W2067328810C2781230642 @default.
• W2067328810 hasConceptScore W2067328810C29730261 @default.
• W2067328810 hasConceptScore W2067328810C71924100 @default.
• W2067328810 hasConceptScore W2067328810C77411442 @default.
• W2067328810 hasConceptScore W2067328810C86803240 @default.
• W2067328810 hasConceptScore W2067328810C90924648 @default.
• W2067328810 hasConceptScore W2067328810C96232424 @default.
• W2067328810 hasLocation W20673288101 @default.
• W2067328810 hasOpenAccess W2067328810 @default.
• W2067328810 hasPrimaryLocation W20673288101 @default.
• W2067328810 hasRelatedWork W183040824 @default.
• W2067328810 hasRelatedWork W1976403743 @default.
• W2067328810 hasRelatedWork W206351842 @default.
• W2067328810 hasRelatedWork W2065770795 @default.
• W2067328810 hasRelatedWork W2080175798 @default.
• W2067328810 hasRelatedWork W2130819559 @default.
• W2067328810 hasRelatedWork W2161979117 @default.
• W2067328810 hasRelatedWork W2188723306 @default.
• W2067328810 hasRelatedWork W2247505779 @default.
• W2067328810 hasRelatedWork W2261062129 @default.
• W2067328810 hasRelatedWork W2261797474 @default.
• W2067328810 hasRelatedWork W2405745152 @default.
• W2067328810 hasRelatedWork W2484253333 @default.
• W2067328810 hasRelatedWork W2514880790 @default.
• W2067328810 hasRelatedWork W2745539538 @default.
• W2067328810 hasRelatedWork W2784416871 @default.
• W2067328810 hasRelatedWork W2792873065 @default.
• W2067328810 hasRelatedWork W2954216702 @default.

• next